LILRB1

ImmunOs Therapeutics Presents Details of Novel Bispecific Anti-Tumor Molecules at ESMO Immuno-Oncology Congress 2023

Retrieved on: 
Monday, December 11, 2023
ESMO, Neoplasm, Immune system, LILRB2, CD47, HLA, Alpha globulin, Doctor of Philosophy, Therapy, KIR3DL1, CDO, Cancer, Inflammation, Myelocyte, CSO, Patient, LILRB1

Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – December 11, 2023 – ImmunOs Therapeutics AG , a biopharmaceutical company pioneering HLA-based therapeutics to create transformational medicines for cancer and inflammation, announced details of its novel multi-functional anti-cancer modality at ESMO Immuno-Oncology Congress 2023 in Geneva (Switzerland) on December 7, 2023.

Key Points: 
  • Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – December 11, 2023 – ImmunOs Therapeutics AG , a biopharmaceutical company pioneering HLA-based therapeutics to create transformational medicines for cancer and inflammation, announced details of its novel multi-functional anti-cancer modality at ESMO Immuno-Oncology Congress 2023 in Geneva (Switzerland) on December 7, 2023.
  • “We already have encouraging in vitro data demonstrating potent anti-tumor efficacy and primary cell data demonstrating an enhanced safety profile compared to competing CD47 targeting molecules,” said Osiris Marroquin Belaunzaran, PhD, CSO and co-founder of ImmunOs Therapeutics.
  • “We believe that HLA molecules can serve as a versatile backbone to develop novel therapies capable of stimulating the immune system of cancer patients to eliminate tumor cells.
  • Moreover, we are also utilizing specific HLA molecules to develop novel therapies to treat inflammatory diseases.”

Elpiscience Announces Studies Presented at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Retrieved on: 
Sunday, November 5, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Neoplasm, Trial of the century, NSCLC, B cell, CD8, NKG2C, SITC, LILRB1, Ligation, CD39, NK, Cancer, Annual general meeting, Tumor microenvironment, Safety, Lymphocyte, TME, Patient, MPE, Vaccine, Medical imaging

Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide, presented studies for its innovative immunotherapeutic molecules at the SITC 2023 Annual Meeting, including KG2A/NKG2C dual-targeting antibody ES015-2, a high affinity LILRB1 specific blocking antibody ES008-a, and the first-in-class anti-CD39/TGF-βRII bifunctional fusion protein ES014.

Key Points: 
  • Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide, presented studies for its innovative immunotherapeutic molecules at the SITC 2023 Annual Meeting, including KG2A/NKG2C dual-targeting antibody ES015-2, a high affinity LILRB1 specific blocking antibody ES008-a, and the first-in-class anti-CD39/TGF-βRII bifunctional fusion protein ES014.
  • CD39-targeted TGFβ “trap” is thus more likely to effectively inhibit tumor progression.
  • Our NKG2A/NKG2C dual targeting antibody ES015-2 can inhibit NKG2A function yet promoting NKG2C action, leading to superior anti-tumor response.
  • ES008-a synergizes with CD47/SIRPα inhibitors in enhancing macrophage phagocytosis of tumor cells.

ImmunOs Therapeutics Presents Overview of Phase 1a/b Trial of Lead Compound IOS-1002

Retrieved on: 
Tuesday, October 24, 2023
ESMO, Therapy, Infrared spectroscopy correlation table, Trial of the century, KIR3DL1, Pembrolizumab, PD-1, Inflammation, Pharmacokinetics, LILRB1, LILRB2, ILT2, DLT, Safety, Cancer, CMO, ILT4, Patient, Immuno-psychiatry, Pharmaceutical industry, MD

The update was presented at ESMO Congress 2023 in Madrid (Spain) on October 23, 2023.

Key Points: 
  • The update was presented at ESMO Congress 2023 in Madrid (Spain) on October 23, 2023.
  • A second cohort of IOS-1002 in combination with pembrolizumab will be initiated after completion of the fifth dose level.
  • The Phase 1a/b trial is expected to enroll over 120 patients.
  • "We are pleased that the trial is progressing as planned," said Christoph Renner, M.D., CMO and co-founder of ImmunOs Therapeutics.

Elpiscience Announces Three Poster Presentations at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Retrieved on: 
Tuesday, October 24, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Tumor microenvironment, SITC, LILRB1, Cancer, NKG2C, Patient, Immunity, Annual general meeting, Poster, Fine chemical, Vaccine

Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide, today announced it will have three poster presentations at the SITC 2023 Annual Meeting taking place November 3-5, 2023, in San Diego.

Key Points: 
  • Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide, today announced it will have three poster presentations at the SITC 2023 Annual Meeting taking place November 3-5, 2023, in San Diego.
  • The posters will highlight its studies on three innovative molecules including a first-in-class NKG2A/NKG2C dual-targeting antibody ES015, a high affinity LILRB1 specific blocking antibody ES008-a, and the first-in-class anti-CD39/TGF-βRII bifunctional fusion protein ES014 which has been proven to be able to deliver TGFβ “trap” to CD39-expressing immune and stroma cells to reshape tumor microenvironment and rejuvenates antitumor immunity.
  • Title: ES015, a first-in-class NKG2A and NKG2C dual-targeting antibody, demonstrated potent anti-tumor immune response

ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA

Retrieved on: 
Tuesday, October 17, 2023
LILRB1, Merck Sharp & Dohme Federal Credit Union, Immuno-psychiatry, Pembrolizumab, Inflammation, Therapy, Merck & Co., Safety, ILT4, Cancer, LILRB2, Merck, HLA, KIR3DL1, ILT2, Patient, Pharmaceutical industry, MD

IOS-1002 is a first-in-class checkpoint inhibitor targeting LILRB1 (ILT2), LILRB2 (ILT4), and KIR3DL1.

Key Points: 
  • IOS-1002 is a first-in-class checkpoint inhibitor targeting LILRB1 (ILT2), LILRB2 (ILT4), and KIR3DL1.
  • ImmunOs is currently enrolling patients in the Phase 1a/b trial, initiated earlier this year, to evaluate the potential of IOS-1002 as a monotherapy and in combination with KEYTRUDA in adult patients with advanced solid tumors.
  • “We are pleased to enter into this agreement for our ongoing Phase 1a/b trial of IOS-1002,” said Christoph Renner, M.D., Chief Medical Officer, and co-founder of ImmunOs.
  • KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

ImmunOs Therapeutics Announces Initiation of Dosing in Phase 1 Trial of Lead Compound IOS-1002

Retrieved on: 
Wednesday, May 24, 2023
LILRB1, ILT2, University, Therapy, LILRB2, HLA, University of Melbourne, Cancer, Pharmacokinetics, Immuno-psychiatry, ILT4, Patient, Immune system, Peter MacCallum Cancer Centre, Trial of the century, KIR3DL1, Safety, Vaccine, Pharmaceutical industry

Schlieren (Zurich Area), Switzerland – May 24, 2023 – ImmunOs Therapeutics AG , a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the initiation of dosing of patients in a Phase 1 trial of its lead program IOS-1002 in Australia.

Key Points: 
  • Schlieren (Zurich Area), Switzerland – May 24, 2023 – ImmunOs Therapeutics AG , a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the initiation of dosing of patients in a Phase 1 trial of its lead program IOS-1002 in Australia.
  • IOS-1002 is a first-in-class checkpoint inhibitor targeting LILRB1 (ILT2), LILRB2 (ILT4), and KIR3DL1 for the treatment of advanced solid tumors.
  • Primary endpoints of the current Phase 1a, first-in-human, open-label, non-randomized, multicenter study will be the safety and tolerability of IOS-1002.
  • "We are excited that our lead compound IOS-1002 has entered into a first-in-human trial and that patients are being dosed," said Sean R. Smith, CEO of ImmunOs Therapeutics.

OncoResponse Presents at AACR 2023 Annual Meeting Preclinical Data Highlighting Dual Antagonist Antibodies Targeting both LILRB1 and LILRB2

Retrieved on: 
Wednesday, April 19, 2023
LILRB1, Immunosuppression, LILRB2, Tumor microenvironment, Antibody, Doctor of Philosophy, Vaccine

SEATTLE, April 19, 2023 /PRNewswire/ -- OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of Elite Cancer Responders, today presented preclinical data highlighting its identification of dual antagonist antibodies targeting both LILRB1 and LILRB2 as potential anti-cancer immunotherapies at the American Association for Cancer Research Annual Meeting in Orlando, Florida.

Key Points: 
  • SEATTLE, April 19, 2023 /PRNewswire/ -- OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of Elite Cancer Responders, today presented preclinical data highlighting its identification of dual antagonist antibodies targeting both LILRB1 and LILRB2 as potential anti-cancer immunotherapies at the American Association for Cancer Research Annual Meeting in Orlando, Florida.
  • "We are excited about the potential of dual antagonist antibodies targeting LILRB1 and LILRB2, as our preclinical research provides compelling evidence of their ability to generate anti-tumor responses.
  • These results support further development of lead anti-LILRB2/1 antibodies, as well as our OR502 anti-LILRB2 clinical candidate, as new approaches for cancer immunotherapy."
  • The presentation highlighted the discovery and characterization of dual antagonist antibodies that target both LILRB1 and LILRB2, inhibitory receptors that promote immunosuppression within the tumor microenvironment.

OncoResponse Announces Presentation of Preclinical Data on Dual Antibodies Targeting LILRB1 and LILRB2 at American Association for Cancer Research Annual Meeting 2023 (AACR 2023)

Retrieved on: 
Wednesday, March 15, 2023
LILRB1, AACR, Doctor of Philosophy, Antibody, LILRB2, Vaccine

"We are pleased to provide our first presentation of preclinical data regarding our dual targeting antibodies for LILRB1 and LILRB2 at the upcoming AACR conference," said Kamal Puri, PhD, Chief Scientific Officer of OncoResponse.

Key Points: 
  • "We are pleased to provide our first presentation of preclinical data regarding our dual targeting antibodies for LILRB1 and LILRB2 at the upcoming AACR conference," said Kamal Puri, PhD, Chief Scientific Officer of OncoResponse.
  • "The presentation will detail both our discovery and preclinical characterization efforts."

ImmunOs Therapeutics´ Lead Program Shows Strong Anti-Tumor Activity In Vivo and In Vitro

Retrieved on: 
Tuesday, November 15, 2022
Degenerative disease, Phagocytosis, LILRB2, Immune system, Macrophage, Lightspeed Venture Partners, Antibody, HLA, Therapy, Patient, PEGS, KIR, Protein, Autoimmunity, LILRB1, NK, ILT4, Cancer, KIR3DL1, ILT2, HCV, HIV, Immuno-psychiatry, Lymphatic system, Pharmaceutical industry, Vaccine, MD

November 15, 2022 ImmunOs Therapeutics AG , a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced promising data for the Companys lead program IOS-1002.

Key Points: 
  • November 15, 2022 ImmunOs Therapeutics AG , a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced promising data for the Companys lead program IOS-1002.
  • The presented data supports IOS-1002 as a first-in-class multi-functional agent which will enter a Phase 1 trial later this year.
  • "We are excited that our lead program IOS-1002 has generated such promising non-clinical data both as a monotherapy and in combination with anti-PD-1," added Sean R. Smith, Chief Executive Officer of ImmunOs Therapeutics.
  • ImmunOs lead program is a multi-functional fusion protein that blocks specific LILRB (leukocyte immunoglobulin-like) and KIR (killer cell immunoglobulin-like) receptors and activates anti-tumor responses.

ImmunOs Therapeutics Raises $74 Million Series B Financing Round

Retrieved on: 
Tuesday, June 7, 2022
Degenerative disease, Saṃsāra, Iron Stone Strategic Capital Partners, Company, Series, LILRB1, ILT2, Doctor of Philosophy, Chairperson, Lightspeed Venture Partners, HLA, CEO, KIR, ILT4, Therapy, Patient, KIR3DL1, LILRB2, Immuno-psychiatry, Novartis, Immune system, Gimv, Antibody, Autoimmune disease, General partnership, Cancer, Vaccine, Pharmaceutical industry, MD, Speed of light

Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA June 7, 2022 ImmunOs Therapeutics AG , a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the closing of an oversubscribed Series B financing round totaling $74 million.

Key Points: 
  • Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA June 7, 2022 ImmunOs Therapeutics AG , a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the closing of an oversubscribed Series B financing round totaling $74 million.
  • "We are delighted to close this significant financing round led by a group of top-tier U.S. and European investors," said Sean R. Smith, CEO of ImmunOs Therapeutics.
  • ImmunOs Therapeutics AG leverages its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases.
  • ImmunOs is also developing antibodies to block the activation of specific HLA protein molecules associated with autoimmune diseases.